Search results
Results from the WOW.Com Content Network
The Model for End-Stage Liver Disease, or MELD, is a scoring system for assessing the severity of chronic liver disease.It was initially developed to predict mortality within three months of surgery in patients who had undergone a transjugular intrahepatic portosystemic shunt (TIPS) procedure, [1] and was subsequently found to be useful in determining prognosis and prioritizing for receipt of ...
MELD-Plus is a risk score to assess severity of chronic liver disease that was resulted from a collaboration between Massachusetts General Hospital and IBM. [1] The score includes nine variables as effective predictors for 90-day mortality after a discharge from a cirrhosis-related admission.
The United Kingdom Model for End-Stage Liver Disease or UKELD is a medical scoring system used to predict the prognosis of patients with chronic liver disease. It is used in the United Kingdom to help determine the need for liver transplantation. [1] It was developed from the MELD score, incorporating the serum sodium level. [2]
Feline hepatic lipidosis, also known as feline fatty liver syndrome, is one of the most common forms of liver disease of cats. [1] The disease officially has no known cause, though obesity is known to increase the risk. [2] The disease begins when the cat stops eating from a loss of appetite, forcing the liver to convert body fat into usable ...
AASLD publishes three major scientific journals on liver disease: Hepatology, Liver Transplantation and Clinical Liver Disease. Clinical Liver Disease [2] is a multimedia review journal. It is clinical in focus and blends text, audio, video, webinars and other multimedia into an interactive resource for all physicians and healthcare providers ...
A liver support system or diachysis is a type of therapeutic device to assist in performing the functions of the liver. Such systems focus either on removing the accumulating toxins (liver dialysis), or providing additional replacement of the metabolic functions of the liver through the inclusion of hepatocytes to the device (bioartificial liver device).
The BRI has proved effective as an index for identifying risk of death from different diseases, [3] disorders of metabolic syndrome, [4] [5] [7] liver disease, [6] cardiovascular diseases in association with sarcopenia, [8] and bone mineral density. [9]
FibroTest has the same prognostic value as a liver biopsy. FibroSure uses quantitative results of five serum biochemical markers, α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, gamma glutamyl transpeptidase (GGT), with a patient’s age and gender to generate a measure of fibrosis and necroinflammatory activity in the liver.